Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02761772
Other study ID # PEP-PIF-2016
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 2016
Est. completion date December 31, 2018

Study information

Verified date March 2019
Source Nordsjaellands Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Miscarriage is a common event associated with severe psychological and social morbidity, further tormenting in women suffering recurrent pregnancy loss (RPL) by at least three consecutive losses.

Ultrasonography and biomarkers have yet to precisely predict viability in pregnancies with symptoms of threatening miscarriage.

A novel biomarker Preimplantation Factor (PIF) derived by the developing embryo might be the key factor for this prediction ameliorating the implantation process by promoting a favorable local immune system in the uterus.

The investigators aim to establish a prospective early pregnancy cohort (PEP-cohort) that includes women throughout the first trimester by both assisted reproductive technology (ART) and spontaneous conceptions. By a combination of consecutive ultrasonographys and blood samples of known predictors of implantation PIF as a predictor of viability will be evaluated.

These data are finally compared to the same data in a retrospective cohort of RPL patients emphasizing the role of PIF.

All collected data will be stored in a Research Biobank for the current studies outlined as well as potential future studies of reproductive medicine in the first trimester.


Description:

The investigators aim to evaluate Preimplantation Factor (PIF) throughout the first trimester we need to employ two settings of recruitment.

Early part:

The PEP in ART (PEP-A) will enroll participants referred for fertility treatment at Rigshospitalet and North Zealand Hospital. Participants all have cryopreserved embryos suitable for frozen embryo transfer in a natural menstrual cycle. No type of ovulation trigger will be employed, as the LH peak is monitored via home urine-LH test.

For a thorough examination of the luteal phase, participants are recalled for blood samples on day 7, 11, 14 and 16 after positive urine-LH test. Hereafter positive serum human chorionic gonadotropin (hCG) denotes a pregnancy and these participants are offered to continue in the later part of the PEP-cohort.

Late part:

PEP in Spontaneous conceptions (PEP-S) represents the sampling of expected normal pregnancies from the local community. Enrolled at the time of the first positive pregnancy test, participants are expected to be included from approximately 5 weeks of gestation. Hereafter participants are recalled every two weeks for blood sampling and transvaginal ultrasonographys of endometrial thickness until a gestational sac and yolk sac are visible for mean sac diameter measuring and eventually the crown-rump-length.

Research biobank All collected data: questionnaires of medical history before enrollment, ultrasonographys and blood samples of progesterone, 17-OH-progesterone, estradiol, alpha-feto-protein (AFP), pregnancy associated placental protein A (PAPP-A), hCG and PIF are stored in a research biobank.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date December 31, 2018
Est. primary completion date September 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility PEP-A

Inclusion Criteria:

1. Women in ART treatment by natural cycle frozen embryo transfer only monitored by urine LH.

2. Age above 18 years.

3. Ability to understand read and write Danish for the informed consent.

4. Planned delivery at the hospitals involved in the project.

Exclusion Criteria:

1. Abnormal uterine anatomy or function already known or estimated at first transvaginal ultrasonography.

2. History of recurrent pregnancy loss.

3. Ongoing or former (at least 12 months of no use) narcotics or alcohol abuse (above 14 units of alcohol per week).

4. Contraindication for pregnancy.

PEP-S

Inclusion Criteria:

1. Spontaneous pregnancy in women above 18 years of age.

2. Gestational age of singleton pregnancy below full eight weeks by first transvaginal ultrasound.

3. Ability to understand read and write Danish for the informed consent.

4. Planned delivery at the hospitals involved in the project.

Exclusion Criteria:

1. All types of ART treatment in the actual pregnancy.

2. Abnormal uterine anatomy or function already known or estimated at first transvaginal ultrasonography.

3. History of recurrent pregnancy loss.

4. Ongoing or former (at least 12 months of no use) narcotics or alcohol abuse (above 14 units of alcohol per week).

5. Contraindication for pregnancy.

Study Design


Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Nordsjaellands Hospital BioIncept LLC, Rigshospitalet, Denmark, Yale University

Outcome

Type Measure Description Time frame Safety issue
Other Research biobank for future use Establishment of a robust research biobank for future studies in blood derived conditions in the first trimester of pregnancy During 2017
Primary PIF in PEP-A Serum PIF by gestational age in the luteal phase During 2018
Primary Prediction model for the risk of spontaneous abortion The ability of serum PIF to predict viability of natural pregnancies with and without other biomarkers, ultrasonographys and medical history data. During 2018
Primary PIF and recurrent pregnancy loss (RPL) Serum PIF levels in a unique retrospective cohort of RPL patients Late 2018
Secondary Hormonal development in the luteal phase Descriptive overview of natural hormones in the luteal phase and their ability to predict pregnancy and live birth rates During 2018
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02408315 - Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE) Phase 3